Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.
Ontology highlight
ABSTRACT: Targeted therapies require information on specific defective signaling pathways or mutations. Advances in genomic technologies and cell biology have led to identification of new therapeutic targets associated with signal-transduction pathways. Survival times of patients with colorectal cancer (CRC) can be extended with combinations of conventional cytotoxic agents and targeted therapies. Targeting EGFR- and VEGFR-signaling systems has been the major focus for treatment of metastatic CRC. However, there are still limitations in their clinical application, and new and better drug combinations are needed. This review provides information on EGFR and VEGF inhibitors, new therapeutic agents in the pipeline targeting EGFR and VEGFR pathways, and those targeting other signal-transduction pathways
SUBMITTER: Seow HF
PROVIDER: S-EPMC4821380 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
ACCESS DATA